VerityRank
Roche Diagnostics (F. Hoffmann-La Roche AG division)
Brand & Manufacturer VerifiedSwitzerland

Roche Diagnostics (F. Hoffmann-La Roche AG division)

Roche Diagnostics

Roche Diagnostics is the diagnostics division of F. Hoffmann-La Roche AG, the world's largest in-vitro diagnostics (IVD) company, headquartered in Rotkreuz, Switzerland. The division was formally established in 1968 and generated CHF 13.8 billion in FY2025 sales, serving clinical laboratories, hospitals, and point-of-care settings in 150+ countries. Roche Diagnostics holds the #1 global market share in IVD across immunoassay, clinical chemistry, molecular diagnostics, and tissue pathology, with its cobas family of analyzers running billions of tests annually. The division's closed-system model — proprietary instruments paired with high-margin consumables and reagents — creates one of the most defensible recurring-revenue engines in medical technology.

Strengths: Roche Diagnostics commands the world's broadest immunodiagnostics test menu, spanning oncology, cardiology, infectious disease, and endocrinology. The cobas integrated laboratory platform delivers unmatched automation for high-volume labs, while the molecular diagnostics franchise (PCR, viral load, MRD) leads the market in infectious disease and oncology monitoring. The division's companion diagnostics partnership model — co-developing tests with pharmaceutical partners — locks in long-term clinical adoption. Pathology sales surged 14% to CHF 1.7 billion in FY2025, fueled by the Ventana tissue-imaging franchise and the $1.05 billion PathAI acquisition. The division also leads in molecular residual disease monitoring through Foundation Medicine and the $595 million SAGA Diagnostics acquisition.
Weaknesses: Roche Diagnostics' closed-system strategy faces pricing pressure in emerging markets, particularly China, where government procurement reforms and VBP tenders have eroded instrument attachment rates. The division's high dependence on consumable pull-through makes it vulnerable when laboratory volumes stagnate. Regulatory scrutiny of data exclusivity and interoperability continues to challenge the closed-ecosystem model in Europe and the United States.
Read More
SwitzerlandFounded 189635,000+CHF$13.8 B15+ manufacturing facilities in… / 100
Listed onSIXROG
Last updated: 2026-11-18 23:30 ET·By VerityRank Research Team·Methodology

Listed market data

ROG · SIX · weeklyHistory →
Market cap
$2.6 B
Share price
CHF 119.83
1Y change
+54.6%
Recent change
-2.1%

11-18 → 11-19

Since first close
×24.1

from 1980-03

Revenue (TTM)
CHF$13.8 B (FY2025)
· updated 2026-11-18 23:30 ETSource ↗

Financial history

Full market history
CHF 0$0CHF 50$1.0 BCHF 100$2.0 BCHF 150$3.0 BCHF 200$4.0 B2025-122026-012026-022026-032026-042026-052026-062026-072026-082026-092026-102026-11
MonthCloseMarket capChange
  • 2026-11CHF 119.83$2.6 B-9.9%
  • 2026-10CHF 133.06$2.9 B-13.0%
  • 2026-09CHF 152.99$3.4 B+21.8%
  • 2026-08CHF 125.57$2.8 B+1.7%
  • 2026-07CHF 123.47$2.7 B-24.6%
  • 2026-06CHF 163.73$3.6 B+15.7%
  • 2026-05CHF 141.52$3.1 B+4.3%
  • 2026-04CHF 135.75$3 B+26.5%
  • 2026-03CHF 107.33$2.4 B-0.5%
  • 2026-02CHF 107.83$2.4 B+10.9%
  • 2026-01CHF 97.24$2.1 B+6.2%
  • 2025-12CHF 91.57$2 B—
Monthly closes · 2025-12 – 2026-11 · Full market history

Ownership & Control

Shareholding as of 2026-06-30
Controlling entity
Publicly held — no controlling shareholder disclosed
Company type
Brand & Manufacturer
Insiders
1.22%
Institutions
103.14%(428 holders)
Free float
98.78%

Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.

In the press

All coverage →5 latest headlines1
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.

Company Overview

Roche Diagnostics is the in-vitro diagnostics (IVD) arm of F. Hoffmann-La Roche AG, the Swiss pharmaceutical and life sciences group founded in Basel in 1896. The diagnostics division was formally constituted in 1968 and today ranks as the world's largest IVD company, holding the #1 global market share in immunodiagnostics and a leading position in molecular diagnostics and tissue pathology. Headquartered in Rotkreuz, Switzerland, the division generated CHF 13.8 billion in FY2025 sales, with 2% organic growth in constant exchange rates despite persistent headwinds in the Chinese market. The division employs approximately 35,000 people and serves clinical laboratories, hospitals, and point-of-care settings across more than 150 countries, with an installed base exceeding 100,000 analyzers globally.

Core Strengths

Roche Diagnostics' competitive moat rests on the industry's broadest immunoassay test menu, spanning more than 100 Elecsys assays covering oncology, cardiology, endocrinology, and infectious disease. The cobas integrated laboratory platform — combining modular pre-analytics, chemistry, immunoassay, and molecular analyzers — delivers industry-leading automation for high-volume laboratories, with the cobas 8000 series processing thousands of patient samples daily. In molecular diagnostics, the division's PCR-based viral load monitoring franchise remains the clinical gold standard for HIV, hepatitis B/C, and cytomegalovirus management, while the newly strengthened molecular residual disease (MRD) portfolio — built through the $595 million acquisition of Saga Diagnostics and the $1.05 billion PathAI deal — positions Roche at the frontier of oncology recurrence monitoring. Pathology sales grew 14% to CHF 1.7 billion in FY2025, driven by the Ventana tissue-imaging franchise and AI-powered digital pathology integration. The division's companion diagnostics model, co-developing targeted tests with pharmaceutical partners for drugs such as Herceptin, Kadcyla, and Tecentriq, creates locked-in clinical adoption and multi-year reagent revenue streams.

Global Presence

Roche Diagnostics maintains a globally distributed manufacturing and R&D footprint. The division's central manufacturing hub in Rotkreuz, Switzerland produces flagship cobas analyzers and core reagent lines, while the German complexes in Mannheim and Penzberg — among the largest diagnostics production sites in the world — cover the full value chain from antibody development to instrument assembly. Molecular diagnostics production is anchored in Pleasanton, California, with additional reagent plants in Tucson, Arizona and Shanghai, China. R&D centers are distributed across Switzerland, Germany, the United States, and Asia, supporting continuous assay development and next-generation platform innovation. The division's sales network spans more than 150 countries, with particular strength in Europe, North America, and Latin America; the Chinese market — historically the division's fastest-growing region — has faced significant headwinds from government procurement reform, VBP tenders, and DRG payment reforms, pressuring growth and prompting a strategic pivot toward value-based disease management solutions.

Challenges & Outlook

Roche Diagnostics enters the 2026-2027 period with a clear strategic agenda: deepening its AI-driven digital diagnostics ecosystem while defending its core IVD franchise against aggressive competitors such as Abbott, Siemens Healthineers, and Danaher. The division's closed-system business model — proprietary instruments paired with consumables — faces growing pressure from China's central procurement reforms and from laboratory consolidation in the United States, where group purchasing organizations demand increasingly aggressive pricing. Currency headwinds, particularly the weakened US dollar, also compressed reported growth in FY2025. Offsetting these pressures, the division is investing heavily in AI-enabled pathology (PathAI), MRD-based oncology monitoring, and next-generation molecular testing for antimicrobial resistance — segments with structurally higher growth rates. Management's stated goal is to return the division to sustained mid-single-digit organic growth by 2027 while expanding operating margins through digital service offerings and manufacturing automation. VerityRank Score of 89/100

Related

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website SIX: ROG (parent F. Hoffmann-La Roche AG) , Roche to Acquire PathAI — Official Press Release
Roche Diagnostics FY2025 Analysis — Fierce Biotech
Roche Diagnostics Global Locations
Roche Foundation Medicine SAGA Diagnostics MRD Platform Update